Claudia A. Chiriboga MD
Neuromuscular Medicine
MD, MPH Columbia Presbyterian Medical Center
180 Fort Washington AvenueNew York, NY 10032
Overview of Dr. Chiriboga
Dr. Claudia Chiriboga is a Child Neurologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Columbia University Irving Medical Center and Morgan Stanley Childrens Hospital of NewYork-Presbyterian. She received her medical degree from University of Buenos Aires and has been in practice 38 years. She is one of 24 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 10 doctors at Morgan Stanley Childrens Hospital of NewYork-Presbyterian who specialize in Child Neurology. She has more than 50 publications and over 500 citings.
Education & Training
Icahn School of Medicine at Mount SinaiResidency, Pediatrics, 1982 - 1985
University of Buenos AiresClass of 1982
Certifications & Licensure
NJ State Medical License Current
NY State Medical License 1985 - 2026
MD State Medical License 1984 - 1986
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Publications & Presentations
PubMed
- 1 citationsJEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri
Journal of Neurology. 2024-08-01 - 5 citationsDigital measures of respiratory and upper limb function in spinal muscular atrophy: design, feasibility, reliability, and preliminary validity of a smartphone sensor-b...Thanneer Malai Perumal, Detlef Wolf, Doris Berchtold, Grégoire Pointeau, Yan-Ping Zhang
Neuromuscular Disorders. 2023-11-01 - 1 citationsCorrection to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study.Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri
Neurology and Therapy. 2023-10-01
Press Mentions
- Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients with Previously-Treated Spinal Muscular Atrophy (SMA)October 12th, 2022
- New Genentech Data for Evrysdi (Risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with Spinal Muscular Atrophy (SMA)June 11th, 2021
Grant Support
- Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)COLUMBIA UNIVERSITY HEALTH SCIENCES2018–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
